Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

111.43 -0.62 (-0.55%)
Streaming Delayed Price Updated: 1:50 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Intel's New CEO Outlines Recovery Strategy. Wall Street Remain Cautious.
Intel's new CEO, Lip-Bu Tan, offered his strategy for turning around the troubled chipmaker in a speech late Monday. But Intel stock fell. 
Via Investor's Business Daily
1 Healthcare Stock to Target This Week and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
Via Benzinga
What Analysts Are Saying About Gilead Sciences Stock
Via Benzinga
The Analyst Verdict: Gilead Sciences In The Eyes Of 14 Experts
Via Benzinga
A Closer Look at Gilead Sciences's Options Market Dynamics
Via Benzinga
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?
The FDA is due to make an approval decision in mid-September for a key product from the top pharma company. 
Via Investor's Business Daily
Exposures Product Safety
No Quick Fix For This Market
Despite the pullback, we have found numerous opportunities which we discuss in this video using technical analysis. 
Via Talk Markets
Topics Stocks / Equities
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Which S&P500 stocks are gapping on Thursday?
Let's have a look at the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed
The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy. 
Via Stocktwits
Stay informed with the top movers within the S&P500 index on Wednesday.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Which S&P500 stocks are gapping on Wednesday?
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding
HIV prevention is a staple in Gilead Sciences' wheelhouse. 
Via Investor's Business Daily
Wednesday's pre-market session: top gainers and losers in the S&P500 index
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements. 
Via Chartmill
Crypto Mixed Post Trump-Putin Call; Trump Eyes HIV Program Cuts, Gilead Dips; Nvidia's AI Lead Secure Through 2028, Says JPMorgan – Top Headlines While The U.S. Slept
Via Benzinga
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides
HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the... 
Via Benzinga
Topics Government
Exposures Political
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack
Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Unpacking the Latest Options Trading Trends in Gilead Sciences
Via Benzinga
Gilead Sciences - Leader In HIV Medicines
The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline. 
Via Talk Markets
Topics Stocks / Equities
Exposures COVID-19
Friday's session: top gainers and losers in the S&P500 index
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Is Gilead Sciences Gaining or Losing Market Support?
Via Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD) Exhibits Quality Stock Traits. Here's Why.
A fundamental analysis of (NASDAQ:GILD): Why GILEAD SCIENCES INC (NASDAQ:GILD) should be investigated by quality investors. 
Via Chartmill
Gilead Presents New HIV Treatment And Cure Research Data
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety in early HIV treatment. 
Via Benzinga
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
From Gilead Sciences, Inc.
Via Business Wire
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
From Gilead Sciences, Inc.
Via Business Wire
These 3 Dividend Stocks Jumped 15% in a Month—More to Come?
Via MarketBeat
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.